Discoidin domain receptors orchestrate cancer progression: A focus on cancer therapies,Cancer Science

当前位置： X-MOL 学术 › Cancer Sci. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Discoidin domain receptors orchestrate cancer progression: A focus on cancer therapies
Cancer Science ( IF 4.5 ) Pub Date : 2020-12-29 , DOI: 10.1111/cas.14789
Yuan Gao ₁ , Jiuli Zhou ₂ , Jin Li ₂

Affiliation

Discoidin domain receptors (DDR), including DDR1 and DDR2, are special types of the transmembrane receptor tyrosine kinase superfamily. DDR are activated by binding to the triple‐helical collagen and, in turn, DDR can activate signal transduction pathways that regulate cell‐collagen interactions involved in multiple physiological and pathological processes such as cell proliferation, migration, apoptosis, and cytokine secretion. Recently, DDR have been found to contribute to various diseases, including cancer. In addition, aberrant expressions of DDR have been reported in various human cancers, which indicates that DDR1 and DDR2 could be new targets for cancer treatment. Considerable effort has been made to design DDR inhibitors and several molecules have shown therapeutic effects in pre–clinical models. In this article, we review the recent literature on the role of DDR in cancer progression, the development status of DDR inhibitors, and the clinical potential of targeting DDR in cancer therapies.

中文翻译：

Discoidin域受体协调癌症进展：专注于癌症治疗

盘状蛋白结构域受体（DDR），包括DDR1和DDR2，是跨膜受体酪氨酸激酶超家族的特殊类型。DDR通过与三螺旋胶原蛋白结合而被激活，然后DDR可以激活信号转导通路，该信号转导通路调节涉及多个生理和病理过程（例如细胞增殖，迁移，凋亡和细胞因子分泌）的细胞胶原相互作用。近来，已经发现DDR导致多种疾病，包括癌症。另外，已经在各种人类癌症中报道了DDR异常表达，这表明DDR1和DDR2可能成为癌症治疗的新靶标。在设计DDR抑制剂方面已经付出了巨大的努力，并且几种分子在临床前模型中显示出治疗效果。在本文中，

更新日期：2021-03-07

点击分享查看原文

点击收藏

公开下载

阅读更多本刊新发论文本刊介绍/投稿指南